Literature DB >> 10910268

Transplantation of the bone marrow microenvironment leads to hematopoietic chimerism without cytoreductive conditioning.

A W Bingaman1, S Y Waitze, D Z Alexander, H R Cho, A Lin, C Tucker-Burden, S R Cowan, T C Pearson, C P Larsen.   

Abstract

BACKGROUND: It has been hypothesized that regimens to induce transplantation tolerance and long-term hematopoietic chimerism require recipient conditioning with whole body irradiation or a cytoablative regimen to create space within the marrow microenvironment to permit pluripotent stem cell engraftment. The purpose of this study was to determine if transplantation of an intact bone marrow microenvironment in the form of a bone graft would permit stable hematopoietic stem cell engraftment, shape the repertoire of developing T cells, and induce donor-specific unresponsiveness in the absence of a conditioning regimen.
METHODS: Fragments of femur were transplanted under the kidney capsule of recipient mice. At defined time points after bone graft transplantation recipients were assayed for chimerism, bone graft viability, and responses to donor and third party alloantigens in vitro and in vivo.
RESULTS: In the absence of an immunological barrier, bone graft transplantation resulted in long-term multi-lineage hematopoietic chimerism in the peripheral blood. Nude bone graft transplantation into SCID recipients resulted in development of donor- derived T cells that underwent negative selection on bone graft derived I-E+ cells within the thymus. Across a fully allogeneic barrier in immunocompetent recipients treated with combined blockade of the CD40 and CD28 pathways bone graft transplantation resulted in long-term donor-specific hyporesponsiveness in vitro and acceptance of donor specific skin grafts.
CONCLUSIONS: Transplantation of bone marrow in the form of a bone graft may facilitate the production of hematopoietic chimerism and lead to long-term donor-specific hyporesponsiveness in the absence of a cytoreductive conditioning regimen.

Entities:  

Mesh:

Year:  2000        PMID: 10910268     DOI: 10.1097/00007890-200006270-00006

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  7 in total

1.  Simultaneous bone marrow and intestine transplantation promotes marrow-derived hematopoietic stem cell engraftment and chimerism.

Authors:  Atsunori Nakao; Hideyoshi Toyokawa; Kei Kimizuka; Michael A Nalesnik; Isao Nozaki; Robert J Bailey; Anthony J Demetris; Thomas E Starzl; Noriko Murase
Journal:  Blood       Date:  2006-04-25       Impact factor: 22.113

Review 2.  Composite tissue transplantation: a rapidly advancing field.

Authors:  K V Ravindra; S Wu; L Bozulic; H Xu; W C Breidenbach; S T Ildstad
Journal:  Transplant Proc       Date:  2008-06       Impact factor: 1.066

3.  Immune Modulation by Mesenchymal Stem Cells.

Authors:  Francesco Bifari; Veronica Lisi; Elda Mimiola; Annalisa Pasini; Mauro Krampera
Journal:  Transfus Med Hemother       Date:  2008-05-16       Impact factor: 3.747

4.  CD40-ligand in primate cardiac allograft and viral immunity.

Authors:  R N Pierson; J E Crowe; S Pfeiffer; J Atkinson; A Azimzadeh; G G Miller
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

5.  The difficulty of eliminating donor leukocyte microchimerism in rat recipients bearing established organ allografts.

Authors:  Tetsuma Kiyomoto; Hideyoshi Toyokawa; Atsunori Nakao; Takashi Kaizu; Anthony J Demetris; Thomas E Starzl; Noriko Murase
Journal:  Transplantation       Date:  2006-02-15       Impact factor: 4.939

6.  Chimerism-based experimental models for tolerance induction in vascularized composite allografts: Cleveland clinic research experience.

Authors:  Maria Siemionow; Aleksandra Klimczak
Journal:  Clin Dev Immunol       Date:  2013-03-14

Review 7.  The need for inducing tolerance in vascularized composite allotransplantation.

Authors:  Kadiyala V Ravindra; Hong Xu; Larry D Bozulic; David D Song; Suzanne T Ildstad
Journal:  Clin Dev Immunol       Date:  2012-10-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.